Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1
148
about 7.1 years
18+
1 site in CA
About this study
This trial is testing a treatment called CD22CART for adults with relapsed or refractory B cell lymphomas. The treatment involves infusing autologous CAR T cells after lymphodepleting chemotherapy. Participants will be followed to see how long they live, if the cancer comes back, and how long their response lasts.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive CD22CART Infusion
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
infusion
Primary: Determine the overall response rate (ORR) in adults with follicular lymphoma (FL) and mantle cell lymphoma (MCL), Maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D)
Secondary: Assess the response rate in adults with relapsed/refractory Hairy cell leukemia (HCL), Lymphoplasmacytic lymphoma (Waldenstrom macroglobulemia) (WM), Burkitt lymphoma (BL), and Marginal Zone lymphoma (MZL)., Evaluate Duration of Response (DOR), Evaluate Overall Survival (OS), Evaluate Progression Free Survival (PFS)
Oncology